Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer

Diana Lüftner; Hans Christian Kolberg; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Christian Jackisch; Frederik Marme; Katharina Keller; Manuel Hörner; Chloë Goossens; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Julia C. Radosa; Maggie Banys-Paluchowski; Achim Wöckel; Nadia Harbeck; Elmar Stickeler; Rupert Bartsch; Bahriye Aktas; Andreas Schneeweiss; Johannes Ettl; Florin Andrei Taran; Wolfgang Janni; Rachel Würstlein; Michael P. Lux

doi:10.1055/a-2515-2366

Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer

Titel in Übersetzung: Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms

Diana Lüftner, Hans Christian Kolberg, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching^*, Christian Jackisch, Frederik Marme, Katharina Keller, Manuel Hörner, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Julia C. Radosa, Maggie Banys-PaluchowskiAchim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin Andrei Taran, Wolfgang Janni, Rachel Würstlein, Michael P. Lux

^*Korrespondierende/r Autor/-in für diese Arbeit

2 Zitate (Scopus)

Abstract

The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.

Titel in Übersetzung	Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms
Originalsprache	Englisch
Zeitschrift	Geburtshilfe und Frauenheilkunde
Jahrgang	85
Ausgabenummer	5
Seiten (von - bis)	507-519
Seitenumfang	13
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2515-2366
Publikationsstatus	Veröffentlicht - 15.05.2025

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

DFG-Fachsystematik

2.22-14 Hämatologie, Onkologie
2.22-21 Gynäkologie und Geburtshilfe

Dokumente

10.1055/a-2515-2366

Weitere Links

Zitieren

Lüftner, D., Kolberg, H. C., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., Keller, K., Hörner, M., Goossens, C., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Radosa, J. C., ... Lux, M. P. (2025). Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 85(5), 507-519. https://doi.org/10.1055/a-2515-2366

@article{fe4a6600fb824a8b83190b62bc7dcb3a,

title = "Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer",

abstract = "The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.",

author = "Diana L{\"u}ftner and Kolberg, \{Hans Christian\} and Hartkopf, \{Andreas D.\} and Fehm, \{Tanja N.\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A.\} and Christian Jackisch and Frederik Marme and Katharina Keller and Manuel H{\"o}rner and Chlo{\"e} Goossens and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Radosa, \{Julia C.\} and Maggie Banys-Paluchowski and Achim W{\"o}ckel and Nadia Harbeck and Elmar Stickeler and Rupert Bartsch and Bahriye Aktas and Andreas Schneeweiss and Johannes Ettl and Taran, \{Florin Andrei\} and Wolfgang Janni and Rachel W{\"u}rstlein and Lux, \{Michael P.\}",

note = "Publisher Copyright: {\textcopyright} 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",

year = "2025",

month = may,

day = "15",

doi = "10.1055/a-2515-2366",

language = "English",

volume = "85",

pages = "507--519",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "5",

}

Lüftner, D, Kolberg, HC, Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Jackisch, C, Marme, F, Keller, K, Hörner, M, Goossens, C, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Radosa, JC, Banys-Paluchowski, M, Wöckel, A, Harbeck, N, Stickeler, E, Bartsch, R, Aktas, B, Schneeweiss, A, Ettl, J, Taran, FA, Janni, W, Würstlein, R & Lux, MP 2025, 'Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, Jg. 85, Nr. 5, S. 507-519. https://doi.org/10.1055/a-2515-2366

TY - JOUR

T1 - Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer

AU - Lüftner, Diana

AU - Kolberg, Hans Christian

AU - Hartkopf, Andreas D.

AU - Fehm, Tanja N.

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A.

AU - Jackisch, Christian

AU - Marme, Frederik

AU - Keller, Katharina

AU - Hörner, Manuel

AU - Goossens, Chloë

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Radosa, Julia C.

AU - Banys-Paluchowski, Maggie

AU - Wöckel, Achim

AU - Harbeck, Nadia

AU - Stickeler, Elmar

AU - Bartsch, Rupert

AU - Aktas, Bahriye

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Taran, Florin Andrei

AU - Janni, Wolfgang

AU - Würstlein, Rachel

AU - Lux, Michael P.

N1 - Publisher Copyright: © 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2025/5/15

Y1 - 2025/5/15

N2 - The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.

AB - The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.

UR - https://www.scopus.com/pages/publications/105005589317

UR - https://www.mendeley.com/catalogue/33a037d9-7a29-3372-91e1-ad830e78fe6a/

U2 - 10.1055/a-2515-2366

DO - 10.1055/a-2515-2366

M3 - Scientific review articles

C2 - 40386501

AN - SCOPUS:105005589317

SN - 0016-5751

VL - 85

SP - 507

EP - 519

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 5

ER -

Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer

Abstract

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren